SlideShare una empresa de Scribd logo
1 de 44
How to read a forest plot?
Samir Haffar M.D.
Assistant Professor of Gastroenterology
Clinical history
• 60-year-old man with acute biliary pancreatitis
• Ranson’s score: 4 – No fever – Normal WBCs
• CECT* on day 7: CT grading system of Balthazar 3
Necrosis score 2
CT severity index 5
• You wonder if prophylactic antibiotics prevents infection
of non-infected pancreatic necrosis & decreases mortality
*CECT: Contrast-Enhanced Computed Tomography
Ranson’s score for gallstone pancreatitis
Age > 70 yr
Blood glucose >220 mg/dl
WBC >18,000/mm3
LDH > 400 IU/L
ASAT > 250 IU/L
At presentation
1 point for each positive factor
Severe acute pancreatitis: ≥ 3
Ranson JHC. Am J Gastroenterol 1982;77:633.
During initial 48 hr
Ht >10% decrease
Serum calcium < 8 mg/dl
Base deficit > 5 mEq/L
BUN > 2 mg/dl increase
Fluid sequestration > 4 L
CT grading system of Balthazar
Grade Description Points
A Normal pancreas 0
Balthazar EJ et al. Radiology 1990 ; 174 : 331 – 6.
B Pancreatic enlargement 1
C Inflammation of pancreas or peripancreatic fat 2
D Single peripancreatic fluid collection 3
E ≥ 2 fluid collections or retroperitoneal air 4
Necrosis score
Necrosis Points
No pancreatic necrosis 0 points
One third of pancreas 2 points
One half of pancreas 4 points
> one half of pancreas 6 points
CT severity index
The index ranges from 0 to 10
Severe acute pancreatitis ≥ 3
CT grading of Balthazar
(0 – 4 points)
Necrosis score
(0 – 6 points)
+
Morgan DE. Clin Gastroenterol Hepatol 2008 ; 6 : 1077 – 1085.
CT Severity Index (CTSI)
Localized fluid collection adjacent to tail: CT grading (3 points)
Lack of enhancement of pancreatic tail: Necrosis <30 % (2 points)
Absence of retroperitoneal air
Bai Y et al. Am J Gastroenterol 2008 ; 103 : 104 – 110.
Antibiotic prophylactic in pancreatic necrosis
Flow diagram
Characteristics of RCTs included in MA
Bai Yu & al. Am J Gastroenterol 2008 ; 103 : 104 – 110.
467 patients included in 7 trials
Data analysis
2 stage statistical process of MA
Statistical power of MA is often very high
• Treatment effect for each study
p value (p)
Relative Risk (RR) or Odds Ratio (OR)
Confidence Intervals (CIs)
Number Needed to Treat (NNT)
• Overall treatment effect
Calculated as weighted average of individual statistics
• p > 0.05 Statistically insignificant
• p < 0.05 Statistically significant
Probability value (p value)
Statistically
significant
Clinically
significant
Doesn't
mean
Risk & Odds
Risk
a
a + b
Risk =
RR: risk patients/risk controls
Odds
a
b
Odds =
OR: odds patients/odds controls
Interpretation of RR & OR
OR or RR should be accompanied by CI
RR or OR > 1
Increased likelihood of outcome in treatment group
RR or OR < 1
Decreased likelihood of outcome in treatment group
RR or OR = 1
No difference of outcome between tt & control group
Confidence Intervals
Value 95 % CI are commonly used
90 or 99% CI are sometimes used
Width of CI Indicates precision of the estimate
Wider the interval, less the precision
CI includes 1 No statistically significant difference
CI doesn’t include 1 Statistically significant difference
Statistical significance & CI
(a) Statistically significant , low precision
(b) Statistically significant, high precision
(c) Not statistically significant, low precision
(d) Not statistically significant, high precision
Glasziou P et al. Evidence based practice workbook. Blackwell, 2nd edition, 2007.
Number Needed to Treat (NNT)
• Relative risk (RR)
Risk in treatment group / risk in control group
• Absolute risk reduction (ARR)
Risk in control group – risk in treatment group
• NNT (expressed in clinically relevant way)
1 /ARR
Statistical methods/overall treatment effect
Larger trials have more influence than smaller ones
Fixed effects model 1
Random effects model 2
Bayesian models3 Controversial
Fixed & random effects
1 Prog Cardiovasc Dis 1985 ; 17 : 335 – 71.
2 Stat Med 1992 ; 11 : 141 – 58.
3 BMJ 1996 ; 313 : 603 – 7.
No single
correct method
Reporting the results
The typical graph for displaying results
of a meta-analysis is called a ‘‘forest plot’’
Antibiotic prophylaxis & prevention of infection
Bai Y et al. Am J Gastroenterol 2008 ; 103 : 104 – 110.
Forest plot
Bai Y et al. Am J Gastroenterol 2008 ; 103 : 104 – 110.
Antibiotic prophylaxis & & prevention of infection
Horizontal line
Scale measuring the treatment effect
Bai Y et al. Am J Gastroenterol 2008 ; 103 : 104 – 110.
Antibiotic prophylaxis & infected necrosis
Vertical line or line of no effect
Treatment & control groups have the same effect
Antibiotic prophylaxis & infected necrosis
Bai Y et al. Am J Gastroenterol 2008 ; 103 : 104 – 110.
Point estimate & CIs for each study
Point estimate (RR or OR) & CI
Gallin JI, Ognibene FP. Principles & practice of clinical research.
A Press, 2nd ed, 2005.
Antibiotic prophylaxis & infected necrosis
Bai Y et al. Am J Gastroenterol 2008 ; 103 : 104 – 110.
Diamond
The diamond
Perera R, Heneghan C, Badenoch D. Statistics Toolkit.
Blackwell Publishing Ltd, Oxford, 1st edition, 2008.
Shows combined point estimate (OR or RR)
& CI for the meta-analysis
Diamond in meta-analysis
Diamond on Left of the line of no effect
Less episodes of outcome of interest in treatment group
Diamond on Right of the line of no effect
MoRe episodes of outcome in treatment group
Diamond touches the line of no effect
No statistically significant difference between groups
Diamond does not touch the line of no effect
Difference between two groups statistically significant
Bai Y et al. Am J Gastroenterol 2008 ; 103 : 104 – 110.
Antibiotic prophylaxis & infected necrosis
The diamond
Shows the overall result of MA
Effect of antibiotic prophylaxis on mortality
Bai Y et al. Am J Gastroenterol 2008 ; 103 : 104 – 110.
The diamond
Interpretation of forest plot
Names on left First authors of primary studies
Black squares RR or OR of individual studies
Black square size Weight of each trial in MA
Horizontal lines 95% confidence intervals
Vertical line Line of no effect (OR or RR = 1)
Diamond Overall treatment effect
Diamond Center Combined treatment effect
Tips of diamond 95% CI
Relative Risk or Odds Ratio?
HP eradication in nonulcer dyspepsia
It is useful to analyze data in both OR & RR
Moayyedi P. Am J Gastroenterol 2004; : 2297-2301.
Using OR Using RR
Significant heterogeneity Reduced heterogeneity
Random or fixed effect modelS?
Prokinetics in nonulcer dyspepsia
Moayyedi P. Am J Gastroenterol 2004; : 2297-2301.
Small trials given more weight than large trials in random effects
Increase estimated overall effect size & widen the 95% CI
Random effects modelFixed effects model
Do the pieces fit together?
Heterogeneity
Simon SD. Statistical evidence in medical trials: What do the data really tell us?
Oxford University Press, Oxford, 1st edition, 2006
Measurement of heterogeneity in MA?
• Qualitative
Forest plot Visual evidence of heterogeneity
Funnel plot Visual evidence of heterogeneity
• Quantitative
X-squared
I-squared Based on Cochran’s Q
Simon SD. Statistical evidence in medical trials: What do the data really tell us?
Oxford University Press, Oxford, 1st edition, 2006
Heterogeneity & forest plot
Hypothetical MA
Some trials with lower C.I. above upper C.I. of other trials
Some lines do not overlap
McGovern D, Summerskill W, Valori R, Levi M. Key topics in EBM.
BIOS Scientific Publishers, 1st Edition, Oxford, 2001.
Funnel plots
Bias detected by simple graphical test
• Plot for each trial RR or OR on x axis
Sample size on y axis
• Absence of bias
Plot should resemble inverted funnel or Christmas tree
• Presence of bias
Plot shows asymmetrical & skewed shape
Ideal funnel plot
The smaller the trial, the larger the distribution of results
Cleophas TJ et all. Statistics applied to clinical trials.
Springer, The Netherlands , 3rd edition, 2006.
Cut Christmas tree
Cleophas TJ et all. Statistics applied to clinical trials.
Springer, The Netherlands , 3rd edition, 2006.
Negative trials not published (missing)
Suspicion of considerable publication bias in this MA
Funnel plot
Publication bias of antibiotics for infected necrosis
Bai Y et al. Am J Gastroenterol 2008 ; 103 : 104 – 110.
Funnel plot
Publication bias of trials of antibiotics for mortality
Bai Y et al. Am J Gastroenterol 2008 ; 103 : 104 – 110.
Quantitative measure of heterogeneity
Many prefer not to use quantitative measure
• X-squared:
Degree of freedom (df) Number of trials in MA – 1
X2 ≈ df No heterogeneity
X2 much greater than df Serious heterogeneity
• I-squared (0 – 100%)
< 25% No heterogeneity
50% – 75% Serious heterogeneity
Simon SD. Statistical evidence in medical trials: What do the data really tell us?
Oxford University Press, Oxford, 1st edition, 2006
Bai Y et al. Am J Gastroenterol 2008 ; 103 : 104 – 110.
Antibiotic prophylaxis & pancreatic necrosis
Heterogeneity
X2 = 7.82 (df 6 – No heterogeneity)
I2 = 23.2% (No or little heterogeneity)
Antibiotic prophylactic effect on mortality
Heterogeneity
Bai Y et al. Am J Gastroenterol 2008 ; 103 : 104 – 110.
X2 = 4.66 (df 6 – No heterogeneity)
I2 = 0 % (No or little heterogeneity)
Thank You

Más contenido relacionado

La actualidad más candente

Journal Club Presentation 1
Journal Club Presentation 1Journal Club Presentation 1
Journal Club Presentation 1Saran A K
 
Cross sectional study-dr.wah
Cross sectional study-dr.wahCross sectional study-dr.wah
Cross sectional study-dr.wahMmedsc Hahm
 
Blinding in clinical trilas
Blinding in clinical trilas Blinding in clinical trilas
Blinding in clinical trilas Tarek Tawfik Amin
 
Writing of Research protocol
Writing of Research protocol Writing of Research protocol
Writing of Research protocol kopalsharma85
 
Interim analysis in clinical trials (1)
Interim analysis in clinical trials (1)Interim analysis in clinical trials (1)
Interim analysis in clinical trials (1)ADITYA CHAKRABORTY
 
Biases in epidemiology
Biases in epidemiologyBiases in epidemiology
Biases in epidemiologySubraham Pany
 
Survival analysis & Kaplan Meire
Survival analysis & Kaplan MeireSurvival analysis & Kaplan Meire
Survival analysis & Kaplan MeireDr Athar Khan
 
Observational descriptive study: case report, case series & ecological study
Observational descriptive study: case report, case series & ecological studyObservational descriptive study: case report, case series & ecological study
Observational descriptive study: case report, case series & ecological studyPrabesh Ghimire
 
Randomisation techniques
Randomisation techniquesRandomisation techniques
Randomisation techniquesUrmila Aswar
 
Type of randomization
Type of randomizationType of randomization
Type of randomizationBharat Kumar
 
Analyzing the randomised control trial (rct)
Analyzing the randomised control trial (rct)Analyzing the randomised control trial (rct)
Analyzing the randomised control trial (rct)Vikash Keshri
 
Meta analysis.pptx
Meta analysis.pptxMeta analysis.pptx
Meta analysis.pptxVishwasATL
 
Biases in meta-analysis
Biases in meta-analysisBiases in meta-analysis
Biases in meta-analysisRizwan S A
 
Randomised Controlled Trial, RCT, Experimental study
Randomised Controlled Trial, RCT, Experimental studyRandomised Controlled Trial, RCT, Experimental study
Randomised Controlled Trial, RCT, Experimental studyDr Lipilekha Patnaik
 
Critical appraisal of meta-analysis
Critical appraisal of meta-analysisCritical appraisal of meta-analysis
Critical appraisal of meta-analysisSamir Haffar
 

La actualidad más candente (20)

Sample size calculation
Sample size calculationSample size calculation
Sample size calculation
 
Forest Plots
Forest PlotsForest Plots
Forest Plots
 
Journal Club Presentation 1
Journal Club Presentation 1Journal Club Presentation 1
Journal Club Presentation 1
 
Odds ratio
Odds ratioOdds ratio
Odds ratio
 
Cross sectional study-dr.wah
Cross sectional study-dr.wahCross sectional study-dr.wah
Cross sectional study-dr.wah
 
Blinding in clinical trilas
Blinding in clinical trilas Blinding in clinical trilas
Blinding in clinical trilas
 
Writing of Research protocol
Writing of Research protocol Writing of Research protocol
Writing of Research protocol
 
Interim analysis in clinical trials (1)
Interim analysis in clinical trials (1)Interim analysis in clinical trials (1)
Interim analysis in clinical trials (1)
 
Biases in epidemiology
Biases in epidemiologyBiases in epidemiology
Biases in epidemiology
 
Survival analysis & Kaplan Meire
Survival analysis & Kaplan MeireSurvival analysis & Kaplan Meire
Survival analysis & Kaplan Meire
 
Observational descriptive study: case report, case series & ecological study
Observational descriptive study: case report, case series & ecological studyObservational descriptive study: case report, case series & ecological study
Observational descriptive study: case report, case series & ecological study
 
Meta analysis
Meta analysisMeta analysis
Meta analysis
 
Randomisation techniques
Randomisation techniquesRandomisation techniques
Randomisation techniques
 
Type of randomization
Type of randomizationType of randomization
Type of randomization
 
Analyzing the randomised control trial (rct)
Analyzing the randomised control trial (rct)Analyzing the randomised control trial (rct)
Analyzing the randomised control trial (rct)
 
Survival analysis
Survival analysisSurvival analysis
Survival analysis
 
Meta analysis.pptx
Meta analysis.pptxMeta analysis.pptx
Meta analysis.pptx
 
Biases in meta-analysis
Biases in meta-analysisBiases in meta-analysis
Biases in meta-analysis
 
Randomised Controlled Trial, RCT, Experimental study
Randomised Controlled Trial, RCT, Experimental studyRandomised Controlled Trial, RCT, Experimental study
Randomised Controlled Trial, RCT, Experimental study
 
Critical appraisal of meta-analysis
Critical appraisal of meta-analysisCritical appraisal of meta-analysis
Critical appraisal of meta-analysis
 

Destacado

Sexual harassment at workplace (Prevention, Prohibition and Redressal) Act 2...
Sexual harassment at workplace (Prevention, Prohibition and Redressal)  Act 2...Sexual harassment at workplace (Prevention, Prohibition and Redressal)  Act 2...
Sexual harassment at workplace (Prevention, Prohibition and Redressal) Act 2...Gaurav Kamboj
 
RMNCH+A strategy: Reproductive, Maternal, neonatal, child and Adolescent Health
RMNCH+A strategy: Reproductive, Maternal, neonatal, child and Adolescent Health RMNCH+A strategy: Reproductive, Maternal, neonatal, child and Adolescent Health
RMNCH+A strategy: Reproductive, Maternal, neonatal, child and Adolescent Health Gaurav Kamboj
 
1. rmncha strategy
1. rmncha strategy1. rmncha strategy
1. rmncha strategyHar Jindal
 
RMNCH+A- NEW INITIAVE OF GOVT OF INDIA
RMNCH+A- NEW INITIAVE OF GOVT OF INDIARMNCH+A- NEW INITIAVE OF GOVT OF INDIA
RMNCH+A- NEW INITIAVE OF GOVT OF INDIADr.Kaushik Nag
 
Meta analysis: Made Easy with Example from RevMan
Meta analysis: Made Easy with Example from RevManMeta analysis: Made Easy with Example from RevMan
Meta analysis: Made Easy with Example from RevManGaurav Kamboj
 

Destacado (12)

Roc
RocRoc
Roc
 
Sexual harassment at workplace (Prevention, Prohibition and Redressal) Act 2...
Sexual harassment at workplace (Prevention, Prohibition and Redressal)  Act 2...Sexual harassment at workplace (Prevention, Prohibition and Redressal)  Act 2...
Sexual harassment at workplace (Prevention, Prohibition and Redressal) Act 2...
 
RMNCH+A strategy: Reproductive, Maternal, neonatal, child and Adolescent Health
RMNCH+A strategy: Reproductive, Maternal, neonatal, child and Adolescent Health RMNCH+A strategy: Reproductive, Maternal, neonatal, child and Adolescent Health
RMNCH+A strategy: Reproductive, Maternal, neonatal, child and Adolescent Health
 
1. rmncha strategy
1. rmncha strategy1. rmncha strategy
1. rmncha strategy
 
Genetics and health
Genetics and health Genetics and health
Genetics and health
 
Ethics in clinical research
Ethics in clinical researchEthics in clinical research
Ethics in clinical research
 
RMNCH+A- NEW INITIAVE OF GOVT OF INDIA
RMNCH+A- NEW INITIAVE OF GOVT OF INDIARMNCH+A- NEW INITIAVE OF GOVT OF INDIA
RMNCH+A- NEW INITIAVE OF GOVT OF INDIA
 
Meta analysis: Made Easy with Example from RevMan
Meta analysis: Made Easy with Example from RevManMeta analysis: Made Easy with Example from RevMan
Meta analysis: Made Easy with Example from RevMan
 
Evidence based medicine
Evidence based medicineEvidence based medicine
Evidence based medicine
 
Evidence Based Medicine by Dr. Harmanjit Singh, GMC, Patiala
Evidence Based Medicine by Dr. Harmanjit Singh, GMC, PatialaEvidence Based Medicine by Dr. Harmanjit Singh, GMC, Patiala
Evidence Based Medicine by Dr. Harmanjit Singh, GMC, Patiala
 
Confidence interval
Confidence intervalConfidence interval
Confidence interval
 
Fever with Rash
Fever with RashFever with Rash
Fever with Rash
 

Similar a How to Read a Forest Plot

Gene Profiling in Clinical Oncology - Slide 10 - H. Rugo - Why genomic tools ...
Gene Profiling in Clinical Oncology - Slide 10 - H. Rugo - Why genomic tools ...Gene Profiling in Clinical Oncology - Slide 10 - H. Rugo - Why genomic tools ...
Gene Profiling in Clinical Oncology - Slide 10 - H. Rugo - Why genomic tools ...European School of Oncology
 
Indonesia Hyperplasia
Indonesia   HyperplasiaIndonesia   Hyperplasia
Indonesia Hyperplasiaguest9dc181
 
Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...
Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...
Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...European School of Oncology
 
BALKAN MCO 2011 - T. Cufer - Chemotherapy: when, why, prognostic factors, reg...
BALKAN MCO 2011 - T. Cufer - Chemotherapy: when, why, prognostic factors, reg...BALKAN MCO 2011 - T. Cufer - Chemotherapy: when, why, prognostic factors, reg...
BALKAN MCO 2011 - T. Cufer - Chemotherapy: when, why, prognostic factors, reg...European School of Oncology
 
Evidence Based Approach to PTE
Evidence Based Approach to PTEEvidence Based Approach to PTE
Evidence Based Approach to PTEKristopher Maday
 
Evidence Based Approach to Pulmonary Thromboembolism
Evidence Based Approach to Pulmonary ThromboembolismEvidence Based Approach to Pulmonary Thromboembolism
Evidence Based Approach to Pulmonary ThromboembolismKristopher Maday
 
VTE and Cancer Healthcare Professional Education
VTE and Cancer Healthcare Professional EducationVTE and Cancer Healthcare Professional Education
VTE and Cancer Healthcare Professional Educationvtesimplified
 
Barretts Brief Version For Upload
Barretts Brief Version For UploadBarretts Brief Version For Upload
Barretts Brief Version For UploadShivakumar Vignesh
 
Cholangiocarcinoma
CholangiocarcinomaCholangiocarcinoma
Cholangiocarcinomaspa718
 
Integrating icosapent ethyl in clinical practice: which patients will benefits?
Integrating icosapent ethyl in clinical practice: which patients will benefits?Integrating icosapent ethyl in clinical practice: which patients will benefits?
Integrating icosapent ethyl in clinical practice: which patients will benefits?Sociedad Española de Cardiología
 
EBRT in breast cancer: Evolution to cutting edge
EBRT in breast cancer: Evolution to cutting edgeEBRT in breast cancer: Evolution to cutting edge
EBRT in breast cancer: Evolution to cutting edgePramod Tike
 
Colorectal cancer - adjuvant Rx - Nicola Tanner
Colorectal cancer - adjuvant Rx - Nicola TannerColorectal cancer - adjuvant Rx - Nicola Tanner
Colorectal cancer - adjuvant Rx - Nicola Tannerwelshbarbers
 
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease BurdenVenous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease BurdenNBCA
 
Antibiotics in the ICU - when, what and how?
Antibiotics in the ICU - when, what and how?Antibiotics in the ICU - when, what and how?
Antibiotics in the ICU - when, what and how?scanFOAM
 

Similar a How to Read a Forest Plot (20)

Meta analysis
Meta analysisMeta analysis
Meta analysis
 
Gene Profiling in Clinical Oncology - Slide 10 - H. Rugo - Why genomic tools ...
Gene Profiling in Clinical Oncology - Slide 10 - H. Rugo - Why genomic tools ...Gene Profiling in Clinical Oncology - Slide 10 - H. Rugo - Why genomic tools ...
Gene Profiling in Clinical Oncology - Slide 10 - H. Rugo - Why genomic tools ...
 
Indonesia Hyperplasia
Indonesia   HyperplasiaIndonesia   Hyperplasia
Indonesia Hyperplasia
 
Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...
Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...
Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...
 
2.1 adj cht cufer
2.1 adj cht cufer2.1 adj cht cufer
2.1 adj cht cufer
 
BALKAN MCO 2011 - T. Cufer - Chemotherapy: when, why, prognostic factors, reg...
BALKAN MCO 2011 - T. Cufer - Chemotherapy: when, why, prognostic factors, reg...BALKAN MCO 2011 - T. Cufer - Chemotherapy: when, why, prognostic factors, reg...
BALKAN MCO 2011 - T. Cufer - Chemotherapy: when, why, prognostic factors, reg...
 
Evidence Based Approach to PTE
Evidence Based Approach to PTEEvidence Based Approach to PTE
Evidence Based Approach to PTE
 
6040630.ppt
6040630.ppt6040630.ppt
6040630.ppt
 
Evidence Based Approach to Pulmonary Thromboembolism
Evidence Based Approach to Pulmonary ThromboembolismEvidence Based Approach to Pulmonary Thromboembolism
Evidence Based Approach to Pulmonary Thromboembolism
 
VTE and Cancer Healthcare Professional Education
VTE and Cancer Healthcare Professional EducationVTE and Cancer Healthcare Professional Education
VTE and Cancer Healthcare Professional Education
 
Wiedermann isicem 2013 where are we now
Wiedermann isicem 2013 where are we nowWiedermann isicem 2013 where are we now
Wiedermann isicem 2013 where are we now
 
Barretts Brief Version For Upload
Barretts Brief Version For UploadBarretts Brief Version For Upload
Barretts Brief Version For Upload
 
Cholangiocarcinoma
CholangiocarcinomaCholangiocarcinoma
Cholangiocarcinoma
 
Integrating icosapent ethyl in clinical practice: which patients will benefits?
Integrating icosapent ethyl in clinical practice: which patients will benefits?Integrating icosapent ethyl in clinical practice: which patients will benefits?
Integrating icosapent ethyl in clinical practice: which patients will benefits?
 
Variceal Bleeding
Variceal Bleeding Variceal Bleeding
Variceal Bleeding
 
EBRT in breast cancer: Evolution to cutting edge
EBRT in breast cancer: Evolution to cutting edgeEBRT in breast cancer: Evolution to cutting edge
EBRT in breast cancer: Evolution to cutting edge
 
Colorectal cancer - adjuvant Rx - Nicola Tanner
Colorectal cancer - adjuvant Rx - Nicola TannerColorectal cancer - adjuvant Rx - Nicola Tanner
Colorectal cancer - adjuvant Rx - Nicola Tanner
 
Dr falk's slides part ii
Dr falk's slides  part iiDr falk's slides  part ii
Dr falk's slides part ii
 
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease BurdenVenous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease Burden
 
Antibiotics in the ICU - when, what and how?
Antibiotics in the ICU - when, what and how?Antibiotics in the ICU - when, what and how?
Antibiotics in the ICU - when, what and how?
 

Más de Samir Haffar

Diagnosis of sliding hiatal hernia
Diagnosis of sliding hiatal herniaDiagnosis of sliding hiatal hernia
Diagnosis of sliding hiatal herniaSamir Haffar
 
Ultrasound of thyroid nodules
Ultrasound of thyroid nodulesUltrasound of thyroid nodules
Ultrasound of thyroid nodulesSamir Haffar
 
Ultrasound of carpal tunnel syndrome
Ultrasound of carpal tunnel syndromeUltrasound of carpal tunnel syndrome
Ultrasound of carpal tunnel syndromeSamir Haffar
 
Assessment of liver fibrosis by us elastography
Assessment of liver fibrosis by us elastographyAssessment of liver fibrosis by us elastography
Assessment of liver fibrosis by us elastographySamir Haffar
 
Doppler ultrasound of visceral arteries
Doppler ultrasound of visceral arteriesDoppler ultrasound of visceral arteries
Doppler ultrasound of visceral arteriesSamir Haffar
 
Ultrasound of groin & anterior abdominal wall hernias
Ultrasound of groin & anterior abdominal wall herniasUltrasound of groin & anterior abdominal wall hernias
Ultrasound of groin & anterior abdominal wall herniasSamir Haffar
 
Extended focus assessment with sonography for trauma
Extended focus assessment with sonography for traumaExtended focus assessment with sonography for trauma
Extended focus assessment with sonography for traumaSamir Haffar
 
Acute appendicitis - Ultrasound first
Acute appendicitis  - Ultrasound firstAcute appendicitis  - Ultrasound first
Acute appendicitis - Ultrasound firstSamir Haffar
 
Carotid intima-media thickness
Carotid intima-media thicknessCarotid intima-media thickness
Carotid intima-media thicknessSamir Haffar
 
Esophageal pH monitoring in pediatrics
Esophageal pH monitoring in pediatricsEsophageal pH monitoring in pediatrics
Esophageal pH monitoring in pediatricsSamir Haffar
 
JNET classification of colo rectal polyps
JNET classification of colo rectal polypsJNET classification of colo rectal polyps
JNET classification of colo rectal polypsSamir Haffar
 
Types of clinical studies
Types of clinical studiesTypes of clinical studies
Types of clinical studiesSamir Haffar
 
MCQs in evidence based practice
MCQs in evidence based practiceMCQs in evidence based practice
MCQs in evidence based practiceSamir Haffar
 
Understanding scientific peer review
Understanding scientific peer reviewUnderstanding scientific peer review
Understanding scientific peer reviewSamir Haffar
 
Artifacts in esophageal high resolution manometry
Artifacts in esophageal high resolution manometryArtifacts in esophageal high resolution manometry
Artifacts in esophageal high resolution manometrySamir Haffar
 
Normal & abnormal swallows in chicago classification version 3.0
Normal & abnormal swallows in chicago classification version 3.0Normal & abnormal swallows in chicago classification version 3.0
Normal & abnormal swallows in chicago classification version 3.0Samir Haffar
 
Indications, examination protocol & results of conventional anorectal manometry
Indications, examination protocol & results of conventional anorectal manometryIndications, examination protocol & results of conventional anorectal manometry
Indications, examination protocol & results of conventional anorectal manometrySamir Haffar
 
Endoanal ultrasound in anal diseases
Endoanal ultrasound in anal diseasesEndoanal ultrasound in anal diseases
Endoanal ultrasound in anal diseasesSamir Haffar
 
Endorectal ultrasound in rectal diseases
Endorectal ultrasound in rectal diseasesEndorectal ultrasound in rectal diseases
Endorectal ultrasound in rectal diseasesSamir Haffar
 
Esophageal motility disorders in Chicago classification v3.0
Esophageal motility disorders in Chicago classification v3.0Esophageal motility disorders in Chicago classification v3.0
Esophageal motility disorders in Chicago classification v3.0Samir Haffar
 

Más de Samir Haffar (20)

Diagnosis of sliding hiatal hernia
Diagnosis of sliding hiatal herniaDiagnosis of sliding hiatal hernia
Diagnosis of sliding hiatal hernia
 
Ultrasound of thyroid nodules
Ultrasound of thyroid nodulesUltrasound of thyroid nodules
Ultrasound of thyroid nodules
 
Ultrasound of carpal tunnel syndrome
Ultrasound of carpal tunnel syndromeUltrasound of carpal tunnel syndrome
Ultrasound of carpal tunnel syndrome
 
Assessment of liver fibrosis by us elastography
Assessment of liver fibrosis by us elastographyAssessment of liver fibrosis by us elastography
Assessment of liver fibrosis by us elastography
 
Doppler ultrasound of visceral arteries
Doppler ultrasound of visceral arteriesDoppler ultrasound of visceral arteries
Doppler ultrasound of visceral arteries
 
Ultrasound of groin & anterior abdominal wall hernias
Ultrasound of groin & anterior abdominal wall herniasUltrasound of groin & anterior abdominal wall hernias
Ultrasound of groin & anterior abdominal wall hernias
 
Extended focus assessment with sonography for trauma
Extended focus assessment with sonography for traumaExtended focus assessment with sonography for trauma
Extended focus assessment with sonography for trauma
 
Acute appendicitis - Ultrasound first
Acute appendicitis  - Ultrasound firstAcute appendicitis  - Ultrasound first
Acute appendicitis - Ultrasound first
 
Carotid intima-media thickness
Carotid intima-media thicknessCarotid intima-media thickness
Carotid intima-media thickness
 
Esophageal pH monitoring in pediatrics
Esophageal pH monitoring in pediatricsEsophageal pH monitoring in pediatrics
Esophageal pH monitoring in pediatrics
 
JNET classification of colo rectal polyps
JNET classification of colo rectal polypsJNET classification of colo rectal polyps
JNET classification of colo rectal polyps
 
Types of clinical studies
Types of clinical studiesTypes of clinical studies
Types of clinical studies
 
MCQs in evidence based practice
MCQs in evidence based practiceMCQs in evidence based practice
MCQs in evidence based practice
 
Understanding scientific peer review
Understanding scientific peer reviewUnderstanding scientific peer review
Understanding scientific peer review
 
Artifacts in esophageal high resolution manometry
Artifacts in esophageal high resolution manometryArtifacts in esophageal high resolution manometry
Artifacts in esophageal high resolution manometry
 
Normal & abnormal swallows in chicago classification version 3.0
Normal & abnormal swallows in chicago classification version 3.0Normal & abnormal swallows in chicago classification version 3.0
Normal & abnormal swallows in chicago classification version 3.0
 
Indications, examination protocol & results of conventional anorectal manometry
Indications, examination protocol & results of conventional anorectal manometryIndications, examination protocol & results of conventional anorectal manometry
Indications, examination protocol & results of conventional anorectal manometry
 
Endoanal ultrasound in anal diseases
Endoanal ultrasound in anal diseasesEndoanal ultrasound in anal diseases
Endoanal ultrasound in anal diseases
 
Endorectal ultrasound in rectal diseases
Endorectal ultrasound in rectal diseasesEndorectal ultrasound in rectal diseases
Endorectal ultrasound in rectal diseases
 
Esophageal motility disorders in Chicago classification v3.0
Esophageal motility disorders in Chicago classification v3.0Esophageal motility disorders in Chicago classification v3.0
Esophageal motility disorders in Chicago classification v3.0
 

Último

Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptkedirjemalharun
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxDr. Dheeraj Kumar
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Classmanuelazg2001
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxKezaiah S
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseSreenivasa Reddy Thalla
 
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...MehranMouzam
 
Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsMedicoseAcademics
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMAANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMADivya Kanojiya
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranTara Rajendran
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurNavdeep Kaur
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Badalona Serveis Assistencials
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxNiranjan Chavan
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAAjennyeacort
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdfDolisha Warbi
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptxDr.Nusrat Tariq
 

Último (20)

Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.ppt
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptx
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Class
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptx
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies Disease
 
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
 
Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes Functions
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMAANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptx
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptx
 

How to Read a Forest Plot

  • 1. How to read a forest plot? Samir Haffar M.D. Assistant Professor of Gastroenterology
  • 2. Clinical history • 60-year-old man with acute biliary pancreatitis • Ranson’s score: 4 – No fever – Normal WBCs • CECT* on day 7: CT grading system of Balthazar 3 Necrosis score 2 CT severity index 5 • You wonder if prophylactic antibiotics prevents infection of non-infected pancreatic necrosis & decreases mortality *CECT: Contrast-Enhanced Computed Tomography
  • 3. Ranson’s score for gallstone pancreatitis Age > 70 yr Blood glucose >220 mg/dl WBC >18,000/mm3 LDH > 400 IU/L ASAT > 250 IU/L At presentation 1 point for each positive factor Severe acute pancreatitis: ≥ 3 Ranson JHC. Am J Gastroenterol 1982;77:633. During initial 48 hr Ht >10% decrease Serum calcium < 8 mg/dl Base deficit > 5 mEq/L BUN > 2 mg/dl increase Fluid sequestration > 4 L
  • 4. CT grading system of Balthazar Grade Description Points A Normal pancreas 0 Balthazar EJ et al. Radiology 1990 ; 174 : 331 – 6. B Pancreatic enlargement 1 C Inflammation of pancreas or peripancreatic fat 2 D Single peripancreatic fluid collection 3 E ≥ 2 fluid collections or retroperitoneal air 4
  • 5. Necrosis score Necrosis Points No pancreatic necrosis 0 points One third of pancreas 2 points One half of pancreas 4 points > one half of pancreas 6 points
  • 6. CT severity index The index ranges from 0 to 10 Severe acute pancreatitis ≥ 3 CT grading of Balthazar (0 – 4 points) Necrosis score (0 – 6 points) + Morgan DE. Clin Gastroenterol Hepatol 2008 ; 6 : 1077 – 1085.
  • 7. CT Severity Index (CTSI) Localized fluid collection adjacent to tail: CT grading (3 points) Lack of enhancement of pancreatic tail: Necrosis <30 % (2 points) Absence of retroperitoneal air
  • 8.
  • 9. Bai Y et al. Am J Gastroenterol 2008 ; 103 : 104 – 110. Antibiotic prophylactic in pancreatic necrosis Flow diagram
  • 10. Characteristics of RCTs included in MA Bai Yu & al. Am J Gastroenterol 2008 ; 103 : 104 – 110. 467 patients included in 7 trials
  • 11. Data analysis 2 stage statistical process of MA Statistical power of MA is often very high • Treatment effect for each study p value (p) Relative Risk (RR) or Odds Ratio (OR) Confidence Intervals (CIs) Number Needed to Treat (NNT) • Overall treatment effect Calculated as weighted average of individual statistics
  • 12. • p > 0.05 Statistically insignificant • p < 0.05 Statistically significant Probability value (p value) Statistically significant Clinically significant Doesn't mean
  • 13. Risk & Odds Risk a a + b Risk = RR: risk patients/risk controls Odds a b Odds = OR: odds patients/odds controls
  • 14. Interpretation of RR & OR OR or RR should be accompanied by CI RR or OR > 1 Increased likelihood of outcome in treatment group RR or OR < 1 Decreased likelihood of outcome in treatment group RR or OR = 1 No difference of outcome between tt & control group
  • 15. Confidence Intervals Value 95 % CI are commonly used 90 or 99% CI are sometimes used Width of CI Indicates precision of the estimate Wider the interval, less the precision CI includes 1 No statistically significant difference CI doesn’t include 1 Statistically significant difference
  • 16. Statistical significance & CI (a) Statistically significant , low precision (b) Statistically significant, high precision (c) Not statistically significant, low precision (d) Not statistically significant, high precision Glasziou P et al. Evidence based practice workbook. Blackwell, 2nd edition, 2007.
  • 17. Number Needed to Treat (NNT) • Relative risk (RR) Risk in treatment group / risk in control group • Absolute risk reduction (ARR) Risk in control group – risk in treatment group • NNT (expressed in clinically relevant way) 1 /ARR
  • 18. Statistical methods/overall treatment effect Larger trials have more influence than smaller ones Fixed effects model 1 Random effects model 2 Bayesian models3 Controversial Fixed & random effects 1 Prog Cardiovasc Dis 1985 ; 17 : 335 – 71. 2 Stat Med 1992 ; 11 : 141 – 58. 3 BMJ 1996 ; 313 : 603 – 7. No single correct method
  • 19. Reporting the results The typical graph for displaying results of a meta-analysis is called a ‘‘forest plot’’
  • 20. Antibiotic prophylaxis & prevention of infection Bai Y et al. Am J Gastroenterol 2008 ; 103 : 104 – 110. Forest plot
  • 21. Bai Y et al. Am J Gastroenterol 2008 ; 103 : 104 – 110. Antibiotic prophylaxis & & prevention of infection Horizontal line Scale measuring the treatment effect
  • 22. Bai Y et al. Am J Gastroenterol 2008 ; 103 : 104 – 110. Antibiotic prophylaxis & infected necrosis Vertical line or line of no effect Treatment & control groups have the same effect
  • 23. Antibiotic prophylaxis & infected necrosis Bai Y et al. Am J Gastroenterol 2008 ; 103 : 104 – 110. Point estimate & CIs for each study
  • 24. Point estimate (RR or OR) & CI Gallin JI, Ognibene FP. Principles & practice of clinical research. A Press, 2nd ed, 2005.
  • 25. Antibiotic prophylaxis & infected necrosis Bai Y et al. Am J Gastroenterol 2008 ; 103 : 104 – 110. Diamond
  • 26. The diamond Perera R, Heneghan C, Badenoch D. Statistics Toolkit. Blackwell Publishing Ltd, Oxford, 1st edition, 2008. Shows combined point estimate (OR or RR) & CI for the meta-analysis
  • 27. Diamond in meta-analysis Diamond on Left of the line of no effect Less episodes of outcome of interest in treatment group Diamond on Right of the line of no effect MoRe episodes of outcome in treatment group Diamond touches the line of no effect No statistically significant difference between groups Diamond does not touch the line of no effect Difference between two groups statistically significant
  • 28. Bai Y et al. Am J Gastroenterol 2008 ; 103 : 104 – 110. Antibiotic prophylaxis & infected necrosis The diamond Shows the overall result of MA
  • 29. Effect of antibiotic prophylaxis on mortality Bai Y et al. Am J Gastroenterol 2008 ; 103 : 104 – 110. The diamond
  • 30. Interpretation of forest plot Names on left First authors of primary studies Black squares RR or OR of individual studies Black square size Weight of each trial in MA Horizontal lines 95% confidence intervals Vertical line Line of no effect (OR or RR = 1) Diamond Overall treatment effect Diamond Center Combined treatment effect Tips of diamond 95% CI
  • 31. Relative Risk or Odds Ratio? HP eradication in nonulcer dyspepsia It is useful to analyze data in both OR & RR Moayyedi P. Am J Gastroenterol 2004; : 2297-2301. Using OR Using RR Significant heterogeneity Reduced heterogeneity
  • 32. Random or fixed effect modelS? Prokinetics in nonulcer dyspepsia Moayyedi P. Am J Gastroenterol 2004; : 2297-2301. Small trials given more weight than large trials in random effects Increase estimated overall effect size & widen the 95% CI Random effects modelFixed effects model
  • 33. Do the pieces fit together? Heterogeneity Simon SD. Statistical evidence in medical trials: What do the data really tell us? Oxford University Press, Oxford, 1st edition, 2006
  • 34. Measurement of heterogeneity in MA? • Qualitative Forest plot Visual evidence of heterogeneity Funnel plot Visual evidence of heterogeneity • Quantitative X-squared I-squared Based on Cochran’s Q Simon SD. Statistical evidence in medical trials: What do the data really tell us? Oxford University Press, Oxford, 1st edition, 2006
  • 35. Heterogeneity & forest plot Hypothetical MA Some trials with lower C.I. above upper C.I. of other trials Some lines do not overlap McGovern D, Summerskill W, Valori R, Levi M. Key topics in EBM. BIOS Scientific Publishers, 1st Edition, Oxford, 2001.
  • 36. Funnel plots Bias detected by simple graphical test • Plot for each trial RR or OR on x axis Sample size on y axis • Absence of bias Plot should resemble inverted funnel or Christmas tree • Presence of bias Plot shows asymmetrical & skewed shape
  • 37. Ideal funnel plot The smaller the trial, the larger the distribution of results Cleophas TJ et all. Statistics applied to clinical trials. Springer, The Netherlands , 3rd edition, 2006.
  • 38. Cut Christmas tree Cleophas TJ et all. Statistics applied to clinical trials. Springer, The Netherlands , 3rd edition, 2006. Negative trials not published (missing) Suspicion of considerable publication bias in this MA
  • 39. Funnel plot Publication bias of antibiotics for infected necrosis Bai Y et al. Am J Gastroenterol 2008 ; 103 : 104 – 110.
  • 40. Funnel plot Publication bias of trials of antibiotics for mortality Bai Y et al. Am J Gastroenterol 2008 ; 103 : 104 – 110.
  • 41. Quantitative measure of heterogeneity Many prefer not to use quantitative measure • X-squared: Degree of freedom (df) Number of trials in MA – 1 X2 ≈ df No heterogeneity X2 much greater than df Serious heterogeneity • I-squared (0 – 100%) < 25% No heterogeneity 50% – 75% Serious heterogeneity Simon SD. Statistical evidence in medical trials: What do the data really tell us? Oxford University Press, Oxford, 1st edition, 2006
  • 42. Bai Y et al. Am J Gastroenterol 2008 ; 103 : 104 – 110. Antibiotic prophylaxis & pancreatic necrosis Heterogeneity X2 = 7.82 (df 6 – No heterogeneity) I2 = 23.2% (No or little heterogeneity)
  • 43. Antibiotic prophylactic effect on mortality Heterogeneity Bai Y et al. Am J Gastroenterol 2008 ; 103 : 104 – 110. X2 = 4.66 (df 6 – No heterogeneity) I2 = 0 % (No or little heterogeneity)

Notas del editor

  1. The initial report of Ranson’s criteria was based on 100 patients (21 of whom underwent early surgery as part of a randomized trial or for uncertainty of diagnosis). The study identified 11 factors that predicted severe diseases (defined as death or an ICU stay beyond 7 days). The 11-point scoring system is measured in 2 stages: 5 initial data points on admission and a further 6 data points within the subsequent 48 hours. The initial report demonstrated a linear relationship between the number of criteria and the likelihood of mortality. Subsequently, modifications were made on the 11-point system for those with gallstone pancreatitis (the original studies were a mixture of alcoholic and biliary pancreatitis).These modifications reduced the number of criteria to 10 for those with gallstone pancreatitis.References:Ranson JHC, Rifkind KM, Roses DF, et al: Prognostic signs and the role of operative management in acute pancreatitis.  SurgGynecolObstet  1974; 139:69. Ranson JHC: Etiological and prognostic factors in human acute pancreatitis: A review.  Am J Gastroenterol  1982; 77:633.
  2. CI is important because it gives an idea about how precise an estimate is. The width of the interval indicates the precision of the estimate. The wider the interval, the less the precision.A very wide interval may indicate that more data should be collected before anything definite can be said about the estimate.
  3. NNT:Number of people who need to receive a treatment in order to achieve the required outcome in one of them.
  4. X-squared:X-squared: Has, on average, a value equal to its degrees of freedomDegree of freedom (df): Number of trials in the MA minus 1 (in this case: 7 – 1 = 6) Interpretation of x2: x-squared = number of trial in MA: no evidence of statistical heterogeneityx-squared much greater than number of trials in MA: serious heterogeneityReference of x-squared:Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. In: Chalmers I, Altman DG, eds. Systematic reviews. London: BMJ Publications, 1995: 48–63.I-squared:&lt; 25% No or little heterogeneity50 – 75 % Serious heterogeneity
  5. X-squared:X-squared: Has, on average, a value equal to its degrees of freedomDegree of freedom (df): Number of trials in the MA minus 1 (in this case: 7 – 1 = 6) Interpretation of x2: x-squared = number of trial in MA: no evidence of statistical heterogeneityx-squared much greater than number of trials in MA: serious heterogeneityReference of x-squared:Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. In: Chalmers I, Altman DG, eds. Systematic reviews. London: BMJ Publications, 1995: 48–63.I-squared:&lt; 25% No or little heterogeneity50 – 75 % Serious heterogeneity